The noticed antimicrobial effects are so called agglutination effects. This will say the pathogens clot together and will be released from the intestine wall and leave the body with the faeces. An extensive literature search was carried out, but the same agglutination effect in relation to (extracts from) fermented vegetables is not described yet, although a lot of literature exists regarding health effects related to fermentation. So apparently Provalor has traced something new and therefor the University of Leiden was requested to analyse Plantibiotics and indicate the active components. The outcome paves the way for patent application.
For the technical and financial viability a number of experiments have been carried out in this phase 1. As the outcome effects the financial viability,a special scheme is developed to calculate the financial effects of the various technical options. The financial viability of Plantibiotics is very acttractive and encourage to go ahead.
The legal investigation did not show any major hick-ups and will be finalized during phase 2. As expected, the marketsearch showed very nice opportunities and indicates that marketing of Plantibiotics should start in NW-Europe followed by other Europe and USA/Canada.
Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)
A major EU-manufacturer of feed-premixes containing functional ingredients, is prepared to act as launching customer. Herewith Provalor has bridged ‘the valley of death’ already now. Consequently Provalor will apply for phase 2 of the SME-instrument soon.
